Advertisement

Ads Placeholder
Loading...

Acarix AB (publ)

ACIXFPNK
Healthcare
Medical - Specialties
$0.03
$0.00(0.00%)
U.S. Market opens in 9h 40m

Acarix AB (publ) Fundamental Analysis

Acarix AB (publ) (ACIXF) shows weak financial fundamentals with a PE ratio of -6.47, profit margin of -6.53%, and ROE of -1.04%. The company generates $0.0B in annual revenue with weak year-over-year growth of -0.62%.

Key Strengths

Cash Position55.28%
PEG Ratio-0.07
Current Ratio4.08

Areas of Concern

ROE-1.04%
Operating Margin-6.52%
We analyze ACIXF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -565.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-565.2/100

We analyze ACIXF's fundamental strength across five key dimensions:

Efficiency Score

Weak

ACIXF struggles to generate sufficient returns from assets.

ROA > 10%
-99.69%

Valuation Score

Excellent

ACIXF trades at attractive valuation levels.

PE < 25
-6.47
PEG Ratio < 2
-0.07

Growth Score

Moderate

ACIXF shows steady but slowing expansion.

Revenue Growth > 5%
-0.62%
EPS Growth > 10%
55.06%

Financial Health Score

Excellent

ACIXF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
4.08

Profitability Score

Weak

ACIXF struggles to sustain strong margins.

ROE > 15%
-104.37%
Net Margin ≥ 15%
-6.53%
Positive Free Cash Flow
No

Key Financial Metrics

Is ACIXF Expensive or Cheap?

P/E Ratio

ACIXF trades at -6.47 times earnings. This suggests potential undervaluation.

-6.47

PEG Ratio

When adjusting for growth, ACIXF's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values Acarix AB (publ) at 8.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.16

EV/EBITDA

Enterprise value stands at -7.43 times EBITDA. This is generally considered low.

-7.43

How Well Does ACIXF Make Money?

Net Profit Margin

For every $100 in sales, Acarix AB (publ) keeps $-6.53 as profit after all expenses.

-6.53%

Operating Margin

Core operations generate -6.52 in profit for every $100 in revenue, before interest and taxes.

-6.52%

ROE

Management delivers $-1.04 in profit for every $100 of shareholder equity.

-1.04%

ROA

Acarix AB (publ) generates $-99.69 in profit for every $100 in assets, demonstrating efficient asset deployment.

-99.69%

Following the Money - Real Cash Generation

Operating Cash Flow

Acarix AB (publ) generates limited operating cash flow of $-47.75M, signaling weaker underlying cash strength.

$-47.75M

Free Cash Flow

Acarix AB (publ) generates weak or negative free cash flow of $-48.50M, restricting financial flexibility.

$-48.50M

FCF Per Share

Each share generates $-0.04 in free cash annually.

$-0.04

FCF Yield

ACIXF converts -15.98% of its market value into free cash.

-15.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.47

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.16

vs 25 benchmark

P/S Ratio

Price to sales ratio

41.74

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.04

vs 25 benchmark

ROA

Return on assets percentage

-1.00

vs 25 benchmark

ROCE

Return on capital employed

-1.26

vs 25 benchmark

How ACIXF Stacks Against Its Sector Peers

MetricACIXF ValueSector AveragePerformance
P/E Ratio-6.4728.54 Better (Cheaper)
ROE-104.37%738.00% Weak
Net Margin-653.46%-43982.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio4.082806.01 Strong Liquidity
ROA-99.69%-14624.00% (disorted) Weak

ACIXF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Acarix AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-76.82%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

90.11%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

90.13%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ